Screening for nasopharyngeal cancer with blood tests
Part of Cancer, Ear, nose & throat, Infections, Mouth & dental clinical trials.
This study compares three different blood tests to see which works best for spotting nasopharyngeal cancer early in people at higher risk. If you live in certain areas of China, you may be able to join.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You voluntarily agree to take part and sign a consent form.
- You are between 30 and 69 years old.
- You live in Guangdong Province or Guangxi Province.
- You are able to come back for long-term follow-up visits.
- You do not have other serious illnesses like heart, lung, liver, or kidney problems, or a weakened immune system.
- You have never had cancer before (other than some skin cancers).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is screening residents aged 30-69 for nasopharyngeal cancer (NPC). It aims to detect cancer early through regular check-ups and follow-up.
This study helps doctors predict which patients with nasopharyngeal cancer (a cancer of the upper throat) will benefit most from additional chemotherapy after radiation treatment. It uses a special blood test and imaging to create a personalized risk score for each patient.
This trial tests whether a special analysis of blood markers and imaging scans can help doctors choose the best combination of chemotherapy and radiation for nasopharyngeal cancer. The goal is to improve outcomes by tailoring treatment to each patient's specific cancer characteristics.
This trial tests whether adjusting chemotherapy based on tumor markers (EBV-DNA) and MRI scans can improve outcomes and reduce side effects for people with nasopharyngeal cancer. If you have stage II or III disease, this study might help guide your treatment more precisely.
This study looks at tissue and blood samples from people already treated for nasopharyngeal carcinoma to find markers that predict how well treatment works and to identify new ways to treat the cancer. It may help doctors personalise care in the future.
This trial tests a new drug, ivonescimab, for people with Epstein-Barr virus (EBV)-positive nasopharyngeal cancer that has come back or spread and no longer responds to standard treatments like chemotherapy and immunotherapy. The goal is to see if this drug can shrink tumors or slow the cancer's growth.
Hear when a new Nasopharyngeal Carcinoma (NPC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.